The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia

Published:2017-05-09 Issue:10 Volume:58 Page:2287-2297
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Aw Andrew¹,Brown Jennifer R.²³

Affiliation:

1. Department of Medicine, Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada;

2. CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;

3. Department of Medicine, Harvard Medical School, Boston, MA, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1312387

Reference87 articles.

1. The B-cell receptor signaling pathway as a therapeutic target in CLL

2. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

3. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

4. Targeting BCL2 for the Treatment of Lymphoid Malignancies

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural product based anticancer drug combination discovery assisted by deep learning and network analysis;Frontiers in Natural Products;2024-01-15

2. Real‐world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience;Hematological Oncology;2023-02-17

3. The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View;Journal of Experimental Pharmacology;2021-10

4. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo;Pharmacological Research;2020-01

5. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia;Current Hematologic Malignancy Reports;2019-09-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3